Appropriately aggregate holistic technologies via accurate expertise. Intrinsicly strategize worldwide initiatives and premium methodologies.
Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial
Journal article
Folegatti PM. et al, (2020), The Lancet, 396, 467 - 478
Factors affecting the species of Campylobacter colonizing chickens reared for meat.
Journal article
Babacan O. et al, (2020), Journal of applied microbiology
A phase I trial evaluating the safety and immunogenicity of a candidate tuberculosis vaccination regimen, ChAdOx1 85A prime - MVA85A boost in healthy UK adults.
Journal article
Wilkie M. et al, (2020), Vaccine, 38, 779 - 789
Cytomegalovirus infection is a risk factor for tuberculosis disease in infants.
Journal article
Müller J. et al, (2019), JCI insight, 4
Author Correction: The influence of haemoglobin and iron on in vitro mycobacterial growth inhibition assays.
Journal article
Tanner R. et al, (2019), Scientific reports, 9
Alternate aerosol and systemic immunisation with a recombinant viral vector for tuberculosis, MVA85A: A phase I randomised controlled trial.
Journal article
Manjaly Thomas Z-R. et al, (2019), PLoS medicine, 16
A CLINICAL CHALLENGE TRIAL DELIVERING AEROSOL BCG AS A CONTROLLED HUMAN INFECTION IN HEALTHY BCG-NAIVE, UK ADULTS: ESTABLISHING OPTIMAL DOSE AND EVALUATING SAFETY
Conference paper
Marshall JL. et al, (2019), AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE, 101, 368 - 369
Tools for Assessing the Protective Efficacy of TB Vaccines in Humans: in vitro Mycobacterial Growth Inhibition Predicts Outcome of in vivo Mycobacterial Infection.
Journal article
Tanner R. et al, (2019), Frontiers in immunology, 10
Immunological correlates of mycobacterial growth inhibition describe a spectrum of tuberculosis infection
Journal article
O’Shea MK. et al, (2018), Scientific Reports, 8
Development of a non-human primate BCG infection model for the evaluation of candidate tuberculosis vaccines
Journal article
Harris SA. et al, (2018), Tuberculosis, 108, 99 - 105
Assay optimisation and technology transfer for multi-site immuno-monitoring in vaccine trials
Journal article
Smith SG. et al, (2017), PLOS ONE, 12, e0184391 - e0184391
The influence of haemoglobin and iron on in vitro mycobacterial growth inhibition assays
Journal article
Tanner R. et al, (2017), Scientific Reports, 7
Correction: Corrigendum: T-cell activation is an immune correlate of risk in BCG vaccinated infants
Journal article
Fletcher HA. et al, (2016), Nature Communications, 7
T-cell activation is an immune correlate of risk in BCG vaccinated infants
Journal article
Fletcher HA. et al, (2016), Nature Communications, 7
A first-in-human phase 1 trial to evaluate the safety and immunogenicity of the candidate tuberculosis vaccine MVA85A-IMX313, administered to BCG-vaccinated adults
Journal article
Minhinnick A. et al, (2016), Vaccine, 34, 1412 - 1421
Optimization of a Human Bacille Calmette-Guérin Challenge Model: A Tool to Evaluate Antimycobacterial Immunity
Journal article
Minhinnick A. et al, (2016), Journal of Infectious Diseases, 213, 824 - 830
A Phase I Trial Evaluating Aerosol Administration Of A Candidate Tb Vaccine, Mva85a, As A Way To Induce Potent Local Cellular Immune Responses And Avoid Anti-Vector Immunity
Conference paper
Thomas Z-RM. et al, (2016), AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 193
S40 Optimisation of a human BCG challenge model
Conference paper
Wilkie MEM. et al, (2015), Thorax, 70, A27.1 - A27
A Phase I, Open-Label Trial, Evaluating the Safety and Immunogenicity of Candidate Tuberculosis Vaccines AERAS-402 and MVA85A, Administered by Prime-Boost Regime in BCG-Vaccinated Healthy Adults
Journal article
Sheehan S. et al, (2015), PLOS ONE, 10, e0141687 - e0141687
Gene Expression and Cytokine Profile Correlate With Mycobacterial Growth in a Human BCG Challenge Model
Journal article
Matsumiya M. et al, (2015), The Journal of Infectious Diseases, 211, 1499 - 1509